World's Best Scientists 2026 revealed!
Eric Bruckert

Eric Bruckert

D-Index & Metrics

Medicine

D-Index
88
Citations
47437
World Ranking
12908
National Ranking
403

Eric Bruckert publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Eric Bruckert sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 433 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Eric Bruckert D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Eric Bruckert sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 88 D-Index — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Eric Bruckert is affiliated with Sorbonne University in France and has a significant body of work in the field of medicine, with a total of 183 publications. Their research spans several subfields including surgery, endocrinology, diabetes and metabolism, economics and econometrics, cancer research, and cardiology and cardiovascular medicine.

The primary topics covered in their research include:

  • Lipoproteins and Cardiovascular Health
  • Cancer, Lipids, and Metabolism
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Systems, Economic Evaluations, Quality of Life
  • Lipid metabolism and disorders
  • Pharmaceutical Economics and Policy
  • Atherosclerosis and Cardiovascular Diseases

Eric Bruckert's recent papers demonstrate engagement with cardiovascular disease, lipid metabolism, and treatment strategies. Notable publications include:

  • Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel, 2020, European Heart Journal
  • Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC), 2021, The Lancet
  • 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance, 2023, European Heart Journal
  • Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM, 2020, Atherosclerosis
  • Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial, 2021, The Lancet Diabetes & Endocrinology

Frequent co-authors in Eric Bruckert's publications include:

  • Antonio Gallo
  • Sophie Béliard
  • Michel Farnier
  • Alain Carrié
  • Franck Boccara

The most common publication venues for Eric Bruckert are:

  • Atherosclerosis (16 publications)
  • European Heart Journal (7 publications)
  • Journal of the American College of Cardiology (5 publications)
  • Journal of clinical lipidology (4 publications)
  • Stroke (4 publications)

Best Publications

  • Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

    Marianne Abifadel;Mathilde Varret;Jean-Pierre Rabès;Delphine Allard

  • Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

    Brian A Ference;Henry N Ginsberg;Ian T. Graham;Kausik K Ray

  • Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

    Borge G. Nordestgaard;M. John Chapman;Steve E. Humphries;Henry N. Ginsberg

  • Sampling variability of liver biopsy in nonalcoholic fatty liver disease.

    Vlad Ratziu;Frédéric Charlotte;Agnès Heurtier;Sophie Gombert

  • Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

    Jean-Philippe Bastard;Claude Jardel;Eric Bruckert;Patricia Blondy

  • Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

    Erik S. Stroes;Paul D. Thompson;Alberto Corsini;Georgirene D. Vladutiu

  • Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

    Jan Borén;M. John Chapman;M. John Chapman;Ronald M. Krauss;Chris J. Packard

  • Liver fibrosis in overweight patients.

    Vlad Ratziu;Philippe Giral;Frederic Charlotte;Eric Bruckert

  • Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

    Marina Cuchel;Eric Bruckert;Henry N. Ginsberg;Frederick J. Raal

  • Familial Hypercholesterolaemia in Children and Adolescents: Gaining Decades of Life by Optimizing Detection and Treatment

    Albert Wiegman;Samuel S. Gidding;Gerald F Watts;M John Chapman

  • Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points - A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine

    Børge G. Nordestgaard;Anne Langsted;Samia Mora;Genovefa Kolovou

  • Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

    Vlad Ratziu;Philippe Giral;Sophie Jacqueminet;Fréderic Charlotte

  • Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance : The GAUSS-2 Randomized, Placebo-Controlled Phase 3 Clinical Trial of Evolocumab

    Erik Stroes;David Colquhoun;David Sullivan;Fernando Civeira

  • The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

    Robert A. Hegele;Henry N. Ginsberg;M. John Chapman;Børge G. Nordestgaard

  • Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

    Gerald F. Watts;Samuel Gidding;Anthony S. Wierzbicki;Peter P. Toth

  • Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.

    Claude Gagné;Daniel Gaudet;Eric Bruckert

  • Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

    Patrick M. Moriarty;Paul D. Thompson;Christopher P. Cannon;John R. Guyton

  • Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

    Boris Hansel;Philippe Giral;Estelle Nobecourt;Sandrine Chantepie

  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

    Steven E. Nissen;Erik Stroes;Ricardo E. Dent-Acosta;Robert S. Rosenson

  • A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke

    Amarenco P;Kim Js;Labreuche J;Charles H

Frequent Co-Authors

Pierre Amarenco
Pierre Amarenco Université Paris Cité
Gerald F. Watts
Gerald F. Watts University of Western Australia
Maciej Banach
Maciej Banach John Paul II Catholic University of Lublin
Kausik K. Ray
Kausik K. Ray Imperial College London
Børge G. Nordestgaard
Børge G. Nordestgaard University of Copenhagen
Erik S.G. Stroes
Erik S.G. Stroes University of Amsterdam
John J.P. Kastelein
John J.P. Kastelein University of Amsterdam
Daniel Gaudet
Daniel Gaudet University of Montreal
Peter P. Toth
Peter P. Toth Johns Hopkins University
Jean Ferrières
Jean Ferrières Federal University of Toulouse Midi-Pyrénées

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Medicine in the USA opens doors to a variety of rewarding healthcare careers, many of which can be accessed through flexible online programs. For those seeking advanced practice roles or specialties, pathways such as the 1 year dnp program online allow for rapid completion of Doctor of Nursing Practice (DNP) degrees. These programs are ideal for nurses aiming to move into leadership or clinical expert roles quickly.

Affordability is a major concern for many students. Prospective DNP candidates can benefit from researching the cheapest dnp programs to minimize student debt while achieving their career goals. Similarly, those interested in starting a medical career faster may consider online vocational pathways such as a fast track medical lpn program, which allows entry into nursing within a short period.

Mental health is another rapidly growing field. The online pmhnp programs offer quick routes to becoming a psychiatric mental health nurse practitioner, addressing critical gaps in mental health care. These diverse online paths make healthcare education far more accessible and convenient for students nationwide.

Best Scientists Citing Eric Bruckert

Trending Scientists